cardiopathies. Cardiac channelopathies are rare, potentially lethal inherited heart conditions, including Long QT Syndrome (LQTS), Short QT Syndrome (SQTS), Brugada Syndrome (BrS) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Cardiomyopathies are potentially lethal progressive diseases that affect the heart muscle including, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Conduction Disease associated with DCM (CD-DCM), and Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). Other cardiopathies include Marfan Syndrome and familial Thoracic Aortic Aneurysms and Aortic Dissections (Marfan/TAAD).
For patients suspected of having an inherited cardiac disease, genetic testing can confirm the diagnosis, provide valuable risk stratification information, guide treatment decisions, identify presymptomatic or silent carriers and better enable genetic counseling.
For more information about the FAMILION family of tests, please visit booth #1321 at 2011 Heart Rhythm Scientific Sessions or online at www.familion.com.
About Transgenomic
Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Product offerings include the WAVE Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,500 systems have been installed in customers' labs in more than 50 countries. The SURVEYOR Mutation Detection Kits provide reagents and protocols for high sensitivity detection of mutations in DNA. HANABI automated chro
'/>"/>
SOURCE Transgenomic, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting2.
Transgenomic, Inc. Reports Third Quarter 2009 Results3.
Transgenomic, Inc. Reports Second Quarter 2009 Results4.
Transgenomic, Inc. Announces Appointment of New Board Members5.
Transgenomic, Inc. Reports First Quarter 2009 Results6.
Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results7.
Transgenomic, Inc. Reports Third Quarter 2008 Results8.
Nanocrystal doping developed by Hebrew University researchers enhances semiconductor nanocrystals9.
Transgenomic Announces Discovery of a Novel Technique Which Enhances Analytic Sensitivity of Standard Sanger Sequencing to 1%10.
DuPont Enhances its PROaccess℠ Business Strategy Through Acquisitions 11.
Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage